Rydén L - Search Results

1

Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.

Uriuda Y, Wang QD, Hatori N, Nordlander R, Sjöquist PO, Mattsson C, Rydén L. Uriuda Y, et al. Among authors: ryden l. J Pharmacol Toxicol Methods. 1998 Mar;39(2):81-9. doi: 10.1016/s1056-8719(98)00006-9. J Pharmacol Toxicol Methods. 1998. PMID: 9694166

2

Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.

Uriuda Y, Wang QD, Grip L, Rydén L, Sjöquist PO, Mattsson C. Uriuda Y, et al. Among authors: ryden l. Cardiovasc Res. 1996 Aug;32(2):320-7. doi: 10.1016/0008-6363(96)00114-9. Cardiovasc Res. 1996. PMID: 8796119

3

Coronary venous drug infusion in the ischaemic-reperfused isolated rat heart.

Uriuda Y, Wang QD, Li XS, Sjoquist PO, Nordlander R, Ryden L. Uriuda Y, et al. Among authors: ryden l. Cardiovasc Res. 1996 Jan;31(1):82-92. Cardiovasc Res. 1996. PMID: 8849592

4

The lipid peroxidation inhibitor indenoindole H290/51 protects myocardium at risk of injury induced by ischemia-reperfusion.

Shimizu M, Wang QD, Sjöquist PO, Rydén L. Shimizu M, et al. Among authors: ryden l. Free Radic Biol Med. 1998 Mar 15;24(5):726-31. doi: 10.1016/s0891-5849(97)00360-2. Free Radic Biol Med. 1998. PMID: 9586802

5

Myocardioprotective effects of felodipine in an antihypertensive dosage: an experimental study in pigs.

Shimizu M, Wang QD, Sjöquist PO, Nordlander R, Rydén L. Shimizu M, et al. Among authors: ryden l. Cardiovasc Drugs Ther. 1998 Mar;12(1):37-45. doi: 10.1023/a:1007733313553. Cardiovasc Drugs Ther. 1998. PMID: 9607131

6

Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury.

Shimizu M, Wang QD, Sjöquist PO, Rydén L. Shimizu M, et al. Among authors: ryden l. J Cardiovasc Pharmacol. 1998 Aug;32(2):231-8. doi: 10.1097/00005344-199808000-00010. J Cardiovasc Pharmacol. 1998. PMID: 9700985

7

Effects of the angiotensin AT1 receptor blocker candesartan on myocardial ischemic/reperfusion injury.

Shimizu M, Sjöquist PO, Wang QD, Rydén L. Shimizu M, et al. Among authors: ryden l. J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S137-42. J Am Soc Nephrol. 1999. PMID: 9892154

8

Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs.

Shimizu M, Wang QD, Sjöquist PO, Rydén L. Shimizu M, et al. Among authors: ryden l. J Cardiovasc Pharmacol. 1999 Oct;34(4):512-7. doi: 10.1097/00005344-199910000-00006. J Cardiovasc Pharmacol. 1999. PMID: 10511125

9

The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion.

Shimizu M, Wang QD, Sjöquist PO, Rydén L. Shimizu M, et al. Among authors: ryden l. Cardiovasc Drugs Ther. 1999 Jul;13(4):347-53. doi: 10.1023/a:1007763618021. Cardiovasc Drugs Ther. 1999. PMID: 10516871

10

Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: an experimental study with the ultrashort-acting calcium antagonist clevidipine.

Segawa D, Sjöquist PO, Wang QD, Gonon A, Nordlander M, Rydén L. Segawa D, et al. Among authors: ryden l. J Cardiovasc Pharmacol. 2000 Sep;36(3):338-43. doi: 10.1097/00005344-200009000-00009. J Cardiovasc Pharmacol. 2000. PMID: 10975591

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

916 results

Search Page

Filters